{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:00:51Z","timestamp":1794373251242,"version":"4.9.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This study was sponsored by Arrowhead Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41591-026-04607-z","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:03:13Z","timestamp":1788944593000},"page":"3339-3350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3904-8590","authenticated-orcid":false,"given":"Mark","family":"O\u2019Carroll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0045-5833","authenticated-orcid":false,"given":"John","family":"Huetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Tomasini-Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1293-3112","authenticated-orcid":false,"given":"Anh","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim D.","family":"Oury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik W.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-2806","authenticated-orcid":false,"given":"Nicholas J.","family":"Leeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9092-4861","authenticated-orcid":false,"given":"Matthias","family":"Salathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the RAGE study consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Blakely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eung gu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Heon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YongChul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Kobielsz-Gembala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenon","family":"Siergiejko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Hajol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Rachel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Roldan","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittipong","family":"Maneechotesuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watchara","family":"Boonsawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittima","family":"Bangpattanasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadwipa","family":"Yuangtrakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"4607_CR1","unstructured":"Global strategy for asthma management and prevention. GINA www.ginasthma.org (2025)."},{"key":"4607_CR2","unstructured":"GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 215 (Global Initiative for Chronic Obstructive Lung Disease, 2025)."},{"key":"4607_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1164\/ajrccm.161.2.16125_2","volume":"161","author":"PJ Barnes","year":"2000","unstructured":"Barnes, P. J. Inhaled corticosteroids are not beneficial in chronicobstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161, 342\u2013344 (2000).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4607_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1370\/afm.240030","volume":"23","author":"WD Pace","year":"2025","unstructured":"Pace, W. D., Callen, E., Gaona-Villarreal, G., Shaikh, A. & Yawn, B. P. Adverse outcomes associated with inhaled corticosteroid use in individuals with chronic obstructive pulmonary disease. Ann. Fam. Med. 23, 127\u2013135 (2025).","journal-title":"Ann. Fam. Med."},{"key":"4607_CR5","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.chest.2023.04.028","volume":"164","author":"NL Lugogo","year":"2023","unstructured":"Lugogo, N. L. et al. Are we ready for asthma remission as a clinical outcome? Chest 164, 831\u2013834 (2023).","journal-title":"Chest"},{"key":"4607_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1476-5381.2012.01984.x","volume":"167","author":"MB Sukkar","year":"2012","unstructured":"Sukkar, M. B. et al. Rage: A new frontier in chronic airways disease. Br. J. Pharmacol. 167, 1161\u20131176 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"4607_CR7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jaci.2019.03.019","volume":"144","author":"TN Perkins","year":"2019","unstructured":"Perkins, T. N. et al. The receptor for advanced glycation end products is a critical mediator of type 2 cytokine signaling in the lungs. J. Allergy Clin. Immunol. 144, 796\u2013808 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"4607_CR8","doi-asserted-by":"publisher","first-page":"1039997","DOI":"10.3389\/fimmu.2023.1039997","volume":"14","author":"KN Killian","year":"2023","unstructured":"Killian, K. N. et al. Rage contributes to allergen driven severe neutrophilic airway inflammation via nlrp3 inflammasome activation in mice. Front. Immunol. 14, 1039997 (2023).","journal-title":"Front. Immunol."},{"key":"4607_CR9","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1165\/rcmb.2014-0027OC","volume":"52","author":"K Waseda","year":"2015","unstructured":"Waseda, K. et al. Emphysema requires the receptor for advanced glycation end-products triggering on structural cells. Am. J. Respir. Cell Mol. Biol. 52, 482\u2013491 (2015).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"4607_CR10","doi-asserted-by":"publisher","first-page":"e0184331","DOI":"10.1371\/journal.pone.0184331","volume":"12","author":"EJ Caraher","year":"2017","unstructured":"Caraher, E. J. et al. Receptor for advanced glycation end-products and world trade center particulate induced lung function loss: a case\u2013cohort study and murine model of acute particulate exposure. PLoS ONE 12, e0184331 (2017).","journal-title":"PLoS ONE"},{"key":"4607_CR11","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1096\/fj.201601155R","volume":"31","author":"H Lee","year":"2017","unstructured":"Lee, H. et al. Blockade of rage ameliorates elastase-induced emphysema development and progression via rage-damp signaling. FASEB J. 31, 2076\u20132089 (2017).","journal-title":"FASEB J."},{"key":"4607_CR12","doi-asserted-by":"publisher","first-page":"e0118979","DOI":"10.1371\/journal.pone.0118979","volume":"10","author":"N Sambamurthy","year":"2015","unstructured":"Sambamurthy, N., Leme, A. S., Oury, T. D. & Shapiro, S. D. The receptor for advanced glycation end products (rage) contributes to the progression of emphysema in mice. PLoS ONE 10, e0118979 (2015).","journal-title":"PLoS ONE"},{"key":"4607_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2174\/1389450119666180820105956","volume":"20","author":"R Armando","year":"2019","unstructured":"Armando, R., Miguel, M., Ileana, G. & Paulina, A. Inhibition of rage axis signaling: a pharmacological challenge. Curr. Drug Targets 20, 340\u2013346 (2019).","journal-title":"Curr. Drug Targets"},{"key":"4607_CR14","unstructured":"Nicholas, A., Bush, E. W., Kasahara, D. I. & Schienebeck, C. M. RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use. US Patent 20220396791\/A1 (Arrowhead Pharmaceuticals, 2022)."},{"key":"4607_CR15","first-page":"PA1289","volume":"62","author":"D Kasahara","year":"2023","unstructured":"Kasahara, D. et al. A clinical-stage inhaled rnai therapeutic for pulmonary inflammation mediates durable rage silencing in nonhuman primates (NHP). Eur. Respir. J. 62, PA1289 (2023).","journal-title":"Eur. Respir. J."},{"key":"4607_CR16","first-page":"256","volume":"53","author":"EW Bush","year":"2018","unstructured":"Bush, E. W. et al. A novel targeted rnai molecule delivery platform for the therapeutic inhibition of enac in cystic fibrosis lung disease. Pediatr. Pulmonol. 53, 256 (2018).","journal-title":"Pediatr. Pulmonol."},{"key":"4607_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaci.2015.03.011","volume":"136","author":"EA Oczypok","year":"2015","unstructured":"Oczypok, E. A. et al. Pulmonary receptor for advanced glycation end-products promotes asthma pathogenesis through il-33 and accumulation of group 2 innate lymphoid cells. J. Allergy Clin. Immunol. 136, 747\u2013756 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"4607_CR18","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1165\/rcmb.2017-0181OC","volume":"59","author":"B Causton","year":"2018","unstructured":"Causton, B. et al. Carma3 mediates allergic lung inflammation in response to alternaria alternata. Am. J. Respir. Cell Mol. Biol. 59, 684\u2013694 (2018).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"4607_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejphar.2014.09.021","volume":"743","author":"MA Gil","year":"2014","unstructured":"Gil, M. A. et al. Anti-inflammatory actions of chemoattractant receptor-homologous molecule expressed on th2 by the antagonist mk-7246 in a novel rat model of Alternaria alternata elicited pulmonary inflammation. Eur. J. Pharmacol. 743, 106\u2013116 (2014).","journal-title":"Eur. J. Pharmacol."},{"key":"4607_CR20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1183\/09031936.05.00035205","volume":"26","author":"R Pellegrino","year":"2005","unstructured":"Pellegrino, R. et al. Interpretative strategies for lung function tests. Eur. Respir. J. 26, 948\u2013968 (2005).","journal-title":"Eur. Respir. J."},{"key":"4607_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1164\/rccm.200801-090OC","volume":"178","author":"MB Drummond","year":"2008","unstructured":"Drummond, M. B. et al. Intersession variability in single-breath diffusing capacity in diabetics without overt lung disease. Am. J. Respir. Crit. Care Med. 178, 225\u2013232 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4607_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaci.2013.12.1035","volume":"134","author":"MA Ullah","year":"2014","unstructured":"Ullah, M. A. et al. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation. J. Allergy Clin. Immunol. 134, 440\u2013450 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"4607_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","volume":"181","author":"WC Moore","year":"2010","unstructured":"Moore, W. C. et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am. J. Respir. Crit. Care Med. 181, 315\u2013323 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4607_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","volume":"178","author":"P Haldar","year":"2008","unstructured":"Haldar, P. et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 178, 218\u2013224 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4607_CR25","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","volume":"160","author":"SE Wenzel","year":"1999","unstructured":"Wenzel, S. E. et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 160, 1001\u20131008 (1999).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4607_CR26","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1183\/09031936.03.00261903","volume":"22","author":"The ENFUMOSA Study Group.","year":"2003","unstructured":"The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur. Respir. J. 22, 470\u2013477 (2003).","journal-title":"Eur. Respir. J."},{"key":"4607_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PM Calverley","year":"2007","unstructured":"Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775\u2013789 (2007).","journal-title":"N. Engl. J. Med."},{"key":"4607_CR28","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha, J. A. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 374, 2222\u20132234 (2016).","journal-title":"N. Engl. J. Med."},{"key":"4607_CR29","doi-asserted-by":"publisher","first-page":"00309","DOI":"10.1183\/23120541.00309-2020","volume":"7","author":"C Kyriakopoulos","year":"2021","unstructured":"Kyriakopoulos, C., Gogali, A., Bartziokas, K. & Kostikas, K. Identification and treatment of T2-low asthma in the era of biologics. ERJ Open Res. 7, 00309\u201302020 (2021).","journal-title":"ERJ Open Res."},{"key":"4607_CR30","doi-asserted-by":"publisher","first-page":"2000528","DOI":"10.1183\/13993003.00528-2020","volume":"57","author":"TSC Hinks","year":"2021","unstructured":"Hinks, T. S. C., Levine, S. J. & Brusselle, G. G. Treatment options in type-2 low asthma. Eur. Respir. J. 57, 2000528 (2021).","journal-title":"Eur. Respir. J."},{"key":"4607_CR31","doi-asserted-by":"publisher","first-page":"917108","DOI":"10.1155\/2010\/917108","volume":"2010","author":"ST Buckley","year":"2010","unstructured":"Buckley, S. T. & Ehrhardt, C. The receptor for advanced glycation end products (RAGE) and the lung. J. Biomed. Biotechnol. 2010, 917108 (2010).","journal-title":"J. Biomed. Biotechnol."},{"key":"4607_CR32","first-page":"40","volume":"23","author":"EA Oczypok","year":"2017","unstructured":"Oczypok, E. A., Perkins, T. N. & Oury, T. D. All the \u201crage\u201d in lung disease: The receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr. Respir. Rev. 23, 40\u201349 (2017).","journal-title":"Paediatr. Respir. Rev."},{"key":"4607_CR33","doi-asserted-by":"publisher","first-page":"e41913","DOI":"10.1371\/journal.pone.0041913","volume":"7","author":"J Beucher","year":"2012","unstructured":"Beucher, J. et al. Ager -429t\/c is associated with an increased lung disease severity in cystic fibrosis. PLoS ONE 7, e41913 (2012).","journal-title":"PLoS ONE"},{"key":"4607_CR34","doi-asserted-by":"publisher","first-page":"2067353","DOI":"10.1155\/2019\/2067353","volume":"2019","author":"M Serveaux-Dancer","year":"2019","unstructured":"Serveaux-Dancer, M. et al. Pathological implications of receptor for advanced glycation end-product (ager) gene polymorphism. Dis. Markers 2019, 2067353 (2019).","journal-title":"Dis. Markers"},{"key":"4607_CR35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1165\/rcmb.2013-0013OC","volume":"49","author":"MP Stogsdill","year":"2013","unstructured":"Stogsdill, M. P. et al. Conditional overexpression of receptors for advanced glycation end-products in the adult murine lung causes airspace enlargement and induces inflammation. Am. J. Respir. Cell Mol. Biol. 49, 128\u2013134 (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"4607_CR36","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.ajpath.2012.06.031","volume":"181","author":"PS Milutinovic","year":"2012","unstructured":"Milutinovic, P. S., Alcorn, J. F., Englert, J. M., Crum, L. T. & Oury, T. D. The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. Am. J. Pathol. 181, 1215\u20131225 (2012).","journal-title":"Am. J. Pathol."},{"key":"4607_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2018.18","volume":"5","author":"AH Burstein","year":"2018","unstructured":"Burstein, A. H. et al. Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 5, 149\u2013154 (2018).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"4607_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07638-2","volume":"7","author":"R Blondonnet","year":"2017","unstructured":"Blondonnet, R. et al. Rage inhibition reduces acute lung injury in mice. Sci. Rep. 7, 7208 (2017).","journal-title":"Sci. Rep."},{"key":"4607_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14667-4","volume":"7","author":"F Zhang","year":"2017","unstructured":"Zhang, F. et al. Srage alleviates neutrophilic asthma by blocking hmgb1\/rage signalling in airway dendritic cells. Sci. Rep. 7, 14268 (2017).","journal-title":"Sci. Rep."},{"key":"4607_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev-med-041316-085215","volume":"69","author":"BI Hudson","year":"2018","unstructured":"Hudson, B. I. & Lippman, M. E. Targeting rage signaling in inflammatory disease. Annu. Rev. Med. 69, 349\u2013364 (2018).","journal-title":"Annu. Rev. Med."},{"key":"4607_CR41","unstructured":"US National Library of Medicine. A Randomized, Double-blind, Placebo-Controlled Phase 2a Study off ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-Induced Mild Asthma https:\/\/clinicaltrials.gov\/study\/nct07241546 (2025)."},{"key":"4607_CR42","doi-asserted-by":"crossref","first-page":"1650016","DOI":"10.1183\/13993003.50016-2016","volume":"52","author":"BL Graham","year":"2018","unstructured":"Graham, B. L. et al. 2017 ers\/ats standards for single-breath carbon monoxide uptake in the lung. Eur. Respir. J. 52, 1650016 (2018).","journal-title":"Eur. Respir. J."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04607-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04607-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04607-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:02:43Z","timestamp":1789480963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04607-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4607"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04607-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.O.\u2019C., N.J.L., T.D.O., T.N.P. and M.S. have received consultation fees from Arrowhead Pharmaceuticals. D.K., J. Hamilton, E.W.B., T.P., L.M., T.R., R.Z. and B.T.-J. are employees of Arrowhead Pharmaceuticals. J. Huetsch is a former employee of Arrowhead Pharmaceuticals.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}